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indeed represent antibodies that can speciﬁcally neutralize
the H9N2 virus but not H3N2, H1N1 or H6N1 inﬂuenza
viruses used as controls. Our result is not unexpected, given
that the H5N1 virus is highly pathogenic and asymptomatic
infection is unlikely. However, infection with the avian H9N2
virus causes only mild symptoms. It is possible that the G1-
like H9N2 virus may be prevalent in the poultry in the area
from where those sera were collected. While only 11 human
cases have been identiﬁed up to date, the avian H9N2 virus
was not considered to infect humans regularly. Because we
found a similar rate of positivity for antibodies against the
seasonal H1N1 virus (Table 1), the detection of antibodies
speciﬁc to the H9N2 virus suggests that natural infection
with this virus in the general population may occur at higher
levels than previously thought. While we have just experi-
enced the swine-origin H1N1 pandemic and continue to clo-
sely watch the activity of the avian H5N1 virus, the potential
for the H9N2 virus or one of its derivatives to cause a pan-
demic should be further assessed.
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Abstract
Dengue is a signiﬁcant mosquito-borne infection in humans, and
its worldwide prevalence is rapidly increasing. In 2010, 83 serum
samples from febrile travellers returning from dengue-endemic
countries to a region in north-eastern Italy, densely infested with
Aedes albopictus, were analysed for dengue virus (DENV). DENV
RNA was detected in 20.5% of patients. By RT-PCR, DENV ser-
otypes 1 and 3 were the most common. DENV must be identi-
ﬁed early in symptomatic travellers returning from high-risk
countries, to prevent outbreaks where potential vectors exist.
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Dengue virus (DENV) is an arthropod-borne RNA virus
(Flaviviridae family) and is transmitted by Aedes mosquitoes
[1]. There are four DENV serotypes, and infection results in
dengue fever or dengue haemorrhagic fever (DHF) [2].
According to the WHO, the annual incidence of dengue
fever/DHF has soared recently [3,4].
In Europe, DENV is not endemic, but DENV-competent
vectors exist [5]. Although this competence is lower for
Aedes albopictus than for Aedes aegypti [6], new autochtho-
nous cycles of infection can be established by infected travel-
lers returning from endemic areas to regions with high
A. albopictus density [7].
Similarly, Chikungunya virus (CHIKV) was introduced to
northern Italy in 2007; A. albopictus was the vector [8], and a
mutation in the CHIKV E1 envelope protein increased
CHIKV infectivity in A. albopictus [9], favouring its survival in
mosquitoes. Thus, vector-borne diseases, typical of tropical
environments, can be introduced and establish themselves in
Europe in appropriate climates [10].
An active regional surveillance programme, comprising cli-
nicians, general practitioners, and virologists, was established
in 2007 in Emilia-Romagna, north-eastern Italy, to ensure
early diagnosis of DENV infections in individuals returning
from high-risk areas. Travellers to endemic countries with
symptoms compatible with DENV or CHIKV infection were
diagnosed by the Regional Reference Centre for Microbio-
logical Emergencies, Clinical Microbiology Unit, St Orsola-
Malpighi University Hospital, Bologna. Suspected cases were
based on clinical and epidemiological criteria according to
the Regional Plan for Control of CHIKV and DENV infection
(http://www.saluter.it/; accessed 21 January 2011).
From 1 January to 31 December 2010, DENV infection
was examined in 83 patients. Laboratory conﬁrmation of
DENV infection entails molecular and serological testing,
based on clinical history [11,12]. If symptom onset is
£9 days, nucleic acid identiﬁcation, antigen detection or viral
isolation is used to diagnose the infection; over >9 days,
serology is preferred (Fig. 1).
DENV non-structural protein (NS1) was measured by
enzyme immunoassay (Platelia Dengue NS1 AG Kit; BioRad,
Segrate, Italy). Multiplex real-time RT-PCR was performed
for DENV RNA [13]. Cell culture is the most common
method for DENV isolation, for which we used Vero cells
[4]. DENV-speciﬁc IgG and IgM were detected by immuno-
ﬂuorescent assay (Euroimmun, Lu¨beck, Germany). All results,
excluding viral culture, were generated within 24 h of sample
arrival to isolate positive patients and implement environ-
mental vector control.
FIG. 1.Workﬂow of the diagnosis of dengue
virus infection in febrile travellers returning
from endemic areas. *Viral isolation was per-
formed when RT-PCR kits were unavailable.
NS1, non-structural protein.
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Five (6.0%) of 83 samples were positive for DENV-speciﬁc
IgG, and were considered to represent past ﬂavivirus infec-
tion/vaccination; one (1.2%) was positive for DENV-speciﬁc
IgG and IgM, and was considered to represent a recent
DENV infection; and 60 (72.3%) did not harbour speciﬁc
antibodies or viral components. Seventeen patients (20.5%)
were in the acute phase of infection; 11 samples tested
positive for NS1 and DENV RNA, and two cases were
RNA-negative and NS1-positive. Only RT-PCR or antigen
detection was performed in four cases, owing to a tempo-
rary shortage of kits—one was tested only by PCR and three
were analysed for NS1; two of the three cases also har-
boured DENV-speciﬁc IgG or IgM, and virus was isolated in
the remaining case. Ten of 17 patients (58.8%) with viral pro-
tein or RNA in the blood had speciﬁc IgG and IgM; seven
(41.2%) tested negative for DENV antibodies.
Whenever possible, a second serum sample, obtained dur-
ing the convalescent phase, was analysed, because increased
DENV antibody titres or seroconversion help to conﬁrm
positive cases (Fig. 1). Follow-up samples were available for
nine of 17 DENV-positive subjects; seroconversion or
increased antibody titre was detected in all nine cases. Thus,
all 17 were conﬁrmed cases of DENV infection, because they
tested positive by RT-PCR, viral isolation, or the presence of
speciﬁc DENV antibodies with seroconversion or increased
antibody titre in the follow-up sample [4].
Fever, rash, headache, asthaenia, arthralgia, retro-orbital
pain and myalgia were the chief symptoms in acute DENV-
infected subjects; three subjects exhibited bleeding with sus-
pected DHF. The mean age of viraemic patients was
38.1 years (range 15–63 years); 12 were male (70.6%).
Because DENV and CHIKV can cause fever and exanthem,
both diagnoses are frequently considered in febrile patients
returning from high-risk areas. Of 23 samples that were posi-
tive for DENV components or speciﬁc antibodies, only
DENV identiﬁcation was requested in 15 cases, whereas
DENV and CHIKV were tested in eight cases; one of these
eight subjects tested positive for CHIKV and DENV antibod-
ies, and was deemed to have had previous exposure to
CHIKV and DENV.
All subjects in the acute phase of DENV infection were
residents of the Emilia-Romagna region and had recently vis-
ited a DENV-endemic area: the Caribbean (n = 1), India
(n = 3), Indonesia (n = 3), Brazil (n = 2), Thailand (n = 4),
Venezuela (n = 3), and Nicaragua-Honduras (n = 1). Twelve
of 17 viraemic patients tested positive for DENV serotype 1
(6/17, 35.3%) or serotype 3 (6/17, 35.3%); typing was not
possible for the ﬁve remaining NS1-positive cases in the
blood, because PCR was not performed or gave negative
results.
The frequency of DENV infection (20.5%) was high in febrile
patients returning from endemic areas to Emilia-Romagna in
2010, demonstrating the efﬁcacy of our regional surveillance
system for DENV. The number of imported DENV cases has
rapidly increased in Emilia-Romagna (Table 1), which is alarm-
ing, considering that the A. albopictus density is high in much of
the region in summer [14] and that local DENV transmission
has been reported in a French region that has a comparable
environment to that of Emilia-Romagna [15].
Because the Aedes mosquito remains uncontrolled in
endemic areas, and because no vaccine exists [1], DENV
infections will continue to escalate, leading to more infected
travellers returning from high-risk areas; this underscores
the need to rapidly diagnose and identify such cases, and pre-
vent local outbreaks in non-endemic areas that are infested
with A. albopictus or other competent vectors.
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TABLE 1. Imported cases of dengue virus (DENV) infection
diagnosed by the Regional Reference Centre for Microbio-












2008 46 3 4
2009 26 6 2
2010 83 17 6
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Abstract
We analysed trends of human immunodeﬁciency virus type 1
(HIV-1) drug resistance during 2007–2009 in the Italian national
HIV drug resistance database ‘ARCA’. Prevalence of resistance
in each year was examined on the basis of the presence of
major International AIDS Society-2009 mutations. Predictors of
resistance were analysed by multivariable logistic regression.
Nine hundred and sixty-six patients were selected. Resistance to
nucleoside reverse transcriptase inhibitors and protease inhibi-
tors showed a signiﬁcant decline with respect to previous sur-
veys. Resistance to any class of drug and three drug classes
remained stable. Independent predictors of three-class resistance
were the number of treatment regimens experienced, prior sub-
optimal nucleoside reverse transcriptase inhibitor therapy and
the current use of ritonavir-boosted protease inhibitors.
Keywords: Antiretroviral therapy, drug resistance mutations,
human immunodeﬁciency virus-1
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Background
The introduction of combination antiretroviral therapy
(cART) has dramatically improved the natural history and
prognosis of human immunodeﬁciency virus type 1 (HIV-1)
infection and AIDS [1]. However, the high propensity of
HIV-1 to develop drug resistance often leads to treatment
failure and progressive exhaustion of treatment options. As a
consequence, continuous surveillance of antiretroviral drug
resistance in large cohorts is warranted [2–5]. In an analysis
of patients failing cART in Italy between 1999 and 2006, we
previously found that the prevalence of any drug resistance
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